WO2010048768A1 - 硝咪唑-氨基酸化合型核素乏氧造影剂及其前体 - Google Patents
硝咪唑-氨基酸化合型核素乏氧造影剂及其前体 Download PDFInfo
- Publication number
- WO2010048768A1 WO2010048768A1 PCT/CN2009/000246 CN2009000246W WO2010048768A1 WO 2010048768 A1 WO2010048768 A1 WO 2010048768A1 CN 2009000246 W CN2009000246 W CN 2009000246W WO 2010048768 A1 WO2010048768 A1 WO 2010048768A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- nitroimidazole
- contrast agent
- compound
- methyl
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 60
- 230000007954 hypoxia Effects 0.000 title claims abstract description 12
- 239000000543 intermediate Substances 0.000 title abstract 3
- 239000012216 imaging agent Substances 0.000 title abstract 2
- 239000002872 contrast media Substances 0.000 claims abstract description 66
- 230000001146 hypoxic effect Effects 0.000 claims abstract description 48
- 230000003902 lesion Effects 0.000 claims abstract description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 78
- 229940024606 amino acid Drugs 0.000 claims description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 150000001413 amino acids Chemical class 0.000 claims description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 29
- 235000001014 amino acid Nutrition 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 25
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 24
- 229960005261 aspartic acid Drugs 0.000 claims description 24
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 22
- -1 small molecule organic compound Chemical class 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 16
- 239000012467 final product Substances 0.000 claims description 16
- 229960001230 asparagine Drugs 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 229940125782 compound 2 Drugs 0.000 claims description 12
- 229940126214 compound 3 Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 235000003704 aspartic acid Nutrition 0.000 claims description 10
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 235000009582 asparagine Nutrition 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000013522 chelant Substances 0.000 claims description 8
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 239000004220 glutamic acid Chemical group 0.000 claims description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 7
- FTZVRGDRIAPBKO-UHFFFAOYSA-N 2-(2-methyl-5-nitroimidazol-1-yl)ethanamine Chemical compound CC1=NC=C([N+]([O-])=O)N1CCN FTZVRGDRIAPBKO-UHFFFAOYSA-N 0.000 claims description 6
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 150000004957 nitroimidazoles Chemical class 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 235000004554 glutamine Nutrition 0.000 claims description 4
- VXLRLTSVUYVBDN-UHFFFAOYSA-N n-ethyl-2-methyl-5-nitroimidazol-1-amine Chemical compound CCNN1C(C)=NC=C1[N+]([O-])=O VXLRLTSVUYVBDN-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000004475 Arginine Chemical group 0.000 claims description 3
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical group OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 3
- 239000004471 Glycine Chemical group 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 239000004472 Lysine Chemical group 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Chemical group SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 229960003067 cystine Drugs 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 2
- 229910052733 gallium Inorganic materials 0.000 claims description 2
- 229910052738 indium Inorganic materials 0.000 claims description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052753 mercury Inorganic materials 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- CSIFGMFVGDBOQC-UHFFFAOYSA-N 3-iminobutanenitrile Chemical compound CC(=N)CC#N CSIFGMFVGDBOQC-UHFFFAOYSA-N 0.000 claims 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 1
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- RYGMFSIKBFXOCR-YPZZEJLDSA-N copper-62 Chemical compound [62Cu] RYGMFSIKBFXOCR-YPZZEJLDSA-N 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 claims 1
- ZLOXYEZYWCTXHU-UHFFFAOYSA-N tenonitrozole Chemical compound S1C([N+](=O)[O-])=CN=C1NC(=O)C1=CC=CS1 ZLOXYEZYWCTXHU-UHFFFAOYSA-N 0.000 claims 1
- 229960004480 tenonitrozole Drugs 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 12
- 206010008132 Cerebral thrombosis Diseases 0.000 abstract description 8
- 201000001429 Intracranial Thrombosis Diseases 0.000 abstract description 8
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 231100000397 ulcer Toxicity 0.000 abstract description 2
- 208000005189 Embolism Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 229960002989 glutamic acid Drugs 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000036770 blood supply Effects 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- BYEQFWZNXANGHB-WNQIDUERSA-N (2s)-2-aminobutanedioic acid;2-methyl-1h-imidazole Chemical compound CC1=NC=CN1.OC(=O)[C@@H](N)CC(O)=O BYEQFWZNXANGHB-WNQIDUERSA-N 0.000 description 4
- 230000009920 chelation Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010051290 Central nervous system lesion Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940058965 antiprotozoal agent against amoebiasis and other protozoal diseases nitroimidazole derivative Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- APFVFJFRJDLVQX-YPZZEJLDSA-N indium-113 Chemical compound [113In] APFVFJFRJDLVQX-YPZZEJLDSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- HIIJZYSUEJYLMX-UHFFFAOYSA-N 1-fluoro-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound FCC(O)CN1C=CN=C1[N+]([O-])=O HIIJZYSUEJYLMX-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 description 1
- CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
- 101100436100 Caenorhabditis elegans asp-6 gene Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000008537 L-aspartic acids Chemical class 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- FNCGNFXGKHSMKJ-QMMMGPOBSA-N ditert-butyl (2s)-2-aminobutanedioate Chemical compound CC(C)(C)OC(=O)C[C@H](N)C(=O)OC(C)(C)C FNCGNFXGKHSMKJ-QMMMGPOBSA-N 0.000 description 1
- GVLZIMQSYQDAHB-QRPNPIFTSA-N ditert-butyl (2s)-2-aminobutanedioate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)C[C@H](N)C(=O)OC(C)(C)C GVLZIMQSYQDAHB-QRPNPIFTSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/95—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by nitrogen atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
Definitions
- the invention relates to a medical radionuclide contrast agent, in particular to a nitrazole-amino acid combination type nuclear hypoxia contrast agent and a precursor thereof.
- Tumors have become one of the main culprits of human health.
- the treatment of malignant tumors often requires surgery, chemical drugs or radiation therapy.
- the treatment of malignant tumors has a great impact on the patients.
- the normal cells have different degrees of killing, resulting in mental pain and physical decline. Therefore, it is expected that early detection and early diagnosis of tumors will result in tumor cells being killed at the time of initiation and bringing new life to patients.
- scientists have long discovered that there are hypoxic cells in malignant tumors, and malignant tumors can be diagnosed by detecting intracellular oxygen conditions. It has been reported to be detected by an oxygen electrode assay, but this method has been limited to some problems in human cells.
- nuclear medicine technology has been used to detect tumor hypoxic cells.
- Nuclear medicine technology uses hypoxic contrast agents to selectively retain in hypoxic cells and detect hypoxia in cells by imaging techniques.
- Nitrazole or a derivative thereof is used as a radiosensitizer, and its metabolism in cells depends on the amount of oxygen available in the cells, and therefore, such compounds can be labeled with radionuclides for imaging of hypoxic cells.
- research on nuclear medicine technology has become a hot spot in radiology, and hypoxic contrast agents have also received attention.
- the technical problem to be solved by the present invention is to overcome the above-mentioned deficiencies and to study a targeted contrast agent for designing hypoxic cells of nitrazole or its derivatives.
- the invention provides a nitrate-nano-amino acid compound nuclides hypoxia contrast agent.
- the contrast agent is composed of a nitrazole-amino acid and a chelated positively charged radionuclide.
- Another object of the present invention is to provide a precursor of a nitrazole-amino acid compound type nuclides hypoxic contrast agent.
- R Asp; Glu; Asn; Gin; Gly; Ser; Lys; Cys; (Cys ⁇ ; Arg.
- the nitroimidazole moiety of this compound has hypoxia targeting by the mechanism that R-NO 2 on the imidazole molecule is converted to R-NH 2 by intracellular nitroreductase in hypoxic cells ( Figure 1 ), due to this special biochemical reaction in hypoxic cells, such contrast agents can accumulate in hypoxic cells.
- the amino acid moiety of the contrast agent molecule of the present invention has a negatively charged free carboxylic acid (R-COCT) and an amino group (-NH 2 ), which can easily chelate a positively charged radionuclide to make such a contrast agent. It is radioactive and obtains hypoxic lesions and tumor images by tracking radionuclides.
- the contrast agent of the invention has dual targeted contrast effects on tumors: 1.
- the rapid growth of tumor cells leads to a lack of blood supply and oxygen fraction in the medulla of the tumor, formation of hypoxic and necrotic tissue, due to the presence of hypoxic tissue in the tumor, Therefore, the contrast agent of the present invention can be used for tumor imaging; 2.
- Normal cells can synthesize the asparagine necessary for growth by themselves, the tumor cells cannot synthesize themselves, and must rely on the host supply, and the contrast agent molecule of the present invention contains asparagine. Therefore, it can also be used for tumor imaging.
- the contrast agent of the present invention is a novel hypoxic target targeted contrast agent.
- the contrast agent can chelate the commonly used radionuclides such as strontium ( 99m Tc), indium ( 113m In), etc., and can be implanted in vivo to enable the radionuclide to be accumulated in the hypoxic (Hypoxia) lesion.
- Tissues and cells, SPECT (ECT) or gamma-ray cameras can be used to track hypoxic lesions, and computerized data can be used to obtain clear images of hypoxic lesions, allowing doctors to accurately diagnose the site of hypoxic lesions. Size and extent.
- the hypoxic lesion refers to a lesion of local tissue and cell necrosis (such as cerebral thrombosis, tumor and other thrombosis, etc.) which is lack of blood supply and oxygen in the local tissue of the human body.
- nitroimidazole derivative described in the contrast agent precursor of the present invention has the following formula (Formula 2):
- R 2 H; CH 3 ; CH 2 -CH 3 ; CH(CH 3 ) 2 ; NH 2 ;
- Nitroimidazole derivatives The amino acids described in the contrast agent of the present invention are aspartic acid (Asp), glutamic acid (Glu), asparagine (Asparagine, Asn), glutamine. Glutamine (Gln), glycine (Glycine, Gly), serine (Serine, Ser), lysine (Lysine, Lys), cysteine (Cysteine, Cys), cystine (Cystine, (Cys) 2 Or arginine (Arginine, Arg), the above 10 amino acids D or L type can be.
- the amino acid to which the nitroimidazole or a derivative thereof is linked to the nitroimidazole or the nitroimidazole derivative in the contrast agent of the present invention may be 1 to 15 amino acids, and the amino acids may be connected in series (Formula 3) or in parallel (Formula 4). It may also be a series and parallel coexistence linkage (formula 5), and the linked amino acids may be a single amino acid arrangement (formula 6), a cross amino acid arrangement (formula 7), or a random amino acid arrangement (formula 8).
- aspartic acid and glutamic acid are both dicarboxylic acid amino acids, linked to nitroimidazole or nitroimidazole derivatives or linked to another amino acid, they may be linked to an alpha carboxylic acid or to a gamma carboxylic acid ( Equation 9).
- Dicarboxylic acid amino acid Contrast agent in the present invention the radionuclide: technetium (99m Tc), indium (113m In, m In), iodine (1311), phosphorus (32 P), mercury (2 .1Hg), gallium (67 Ga , 68 Ga), ⁇ ( 85 Sr), chromium ( 51 Cr), ⁇ ( 133 Xe), ⁇ ( 2 ( ) 1 T1 ), ⁇ ( 81m Kr ), ⁇ ( 86 Rb ) or copper ( ⁇ Cu
- the contrast agent of the present invention may be a single intramolecular chelate radionuclide (Formula 10) or a bimolecular chelate radionuclide (Formula 11).
- a further object of the present invention is to provide a method for preparing a nitrazole-amino acid-type nuclides hypoxic contrast agent precursor.
- the contrast agent of the present invention is an amino group (-NH 2 ) on the molecule of 1-(2-aminoethyl)-2-methyl-5-nitroimidazole and an alpha carboxylic acid (-COOH) on the L-aspartate molecule.
- 2-(Isobutylamino)-4-phenyl-L-aspartate (3-30 mmol) was dissolved in 50-500 ml of anhydrous dichloromethane solution, and triethylamine (3-30 mmol) was added in that order.
- 1-(2-Ethylamino)-2-methyl-5-nitroimidazole (3-30 mmol) and diacetyl cyanide (3-30 mmol) were stirred at room temperature. 50-500ml of dichloromethane was added to the reaction solution, the reaction solution was washed with 100-120ml of water, dried over anhydrous MgS0 4.
- the chemical reaction step of the method of the invention is simple, and the final reaction product (aspartic acid-metimidazole) (Fig. 2, 3, 4) has a high yield, and the purification method is simple, and the crude product (aspartic acid-methylnitrite) The purity can reach 95%, and the radio purity after chelation of the radionuclide is high (Fig. 5).
- Still another object of the present invention is to provide an application of a nitrazole-amino acid complex type nuclides hypoxic contrast agent in the preparation of an image contrast agent.
- Still another object of the present invention is to provide a nitrazole-amino acid compound type nuclides hypoxic contrast agent for use in diagnosing a malignant tumor, post-surgical evaluation of a tumor, post-tumor evaluation, or brain scan to assess a thrombus-induced cerebral hypoxic lesion. use.
- Cerebral thrombosis It is caused by cerebral thrombosis, which causes hypoxia and necrosis of brain cells, and finally causes stroke to be a common disease in middle-aged people.
- Clinically its early diagnosis, timely detection of lesions for treatment, "window period" is crucial for the patient's prognosis.
- CT and magnetic resonance imaging (MRI) are difficult to diagnose early on cerebral thrombosis and cerebral hemorrhage, and the clinical treatment of these two brain lesions is different.
- the contrast agent of the present invention is a functional molecular imaging contrast agent, so the contrast agent can distinguish the above two brain lesions at an early stage.
- the contrast agent of the present invention can also use images to track the recovery state after cerebral thrombosis treatment.
- tumor The rapid growth of tumor cells leads to a lack of blood supply and oxygen in the medulla of the tumor, forming hypoxic and necrotic tissue.
- This type of contrast agent also has a good special imaging effect on tumors, and has a highly sensitive imaging of tumors (can show tumors >1.5).
- 3D tumor images can be obtained by SPECT (ECT), which facilitates the early diagnosis of the location, size and extent of the tumor.
- the contrast agent of the present invention can also periodically image the tumor, and use images to track and judge the therapeutic effect of the tumor and the extent to which the tumor is resistant to the treatment.
- the nitrazole-amino acid complex type nuclide hypoxia contrast agent of the present invention can be used for imaging contrast agents such as cerebral thrombosis, tumor or other hypoxic lesions such as ulcers and thrombus plugs.
- the contrast agent of the invention has dual targeted contrast effects on tumors: 1.
- the rapid growth of tumor cells leads to a lack of blood supply and oxygen fraction in the medulla of the tumor, formation of hypoxic and necrotic tissue, due to the presence of hypoxic tissue in the tumor,
- the contrast agent of the invention can be used for tumor imaging; 2.
- the normal cells can synthesize the asparagine necessary for growth by themselves, the tumor cells cannot synthesize themselves, and must rely on the host supply, and the contrast agent molecule of the invention contains asparagine, and can also Used for tumor targeting tracking.
- the contrast agent of the present invention is a novel hypoxic lesion targeted tracking contrast agent.
- the contrast agent can chelate the clinically applied radionuclide
- hypoxic lesions eg: m ( 99m Tc), indium ( 113m In), etc.
- injected in vivo can target radionuclides to tissues and cells accumulating in hypoxic (Hyppxia) lesions, by SPECT (ECT) or ⁇ -ray
- ECT SPECT
- ⁇ -ray The camera can track hypoxic lesions and obtain clear images of hypoxic lesions by computer data processing, so that doctors can accurately diagnose the location, size and extent of hypoxic lesions.
- Medical hypoxic lesions refer to lesions in the body's local tissues that lack blood supply and oxygen, leading to local tissue and cell necrosis (eg, cerebral thrombosis, tumors, and other thrombosis).
- the nuclides hypoxic contrast agent of the present invention can be used for diagnosing malignant tumors, post-operative evaluation of tumors, post-treatment of tumors, and brain scans (evaluation of cerebral hypoxic lesions caused by thrombosis).
- the preparation method has the advantages of simple preparation process, convenient use and large clinical application value.
- R-N0 spent on intracellular imidazole nitrate oxygen molecule is converted to 2
- R-NH 2 is a schematic view of
- Figure 13 Image of rat (breast cancer on the leg) after intravenous injection of radionuclide contrast agent on ⁇ -illuminator
- the chemical reaction step (Formula 13) is simple, and the final reaction product (MNA) (Figs. 2, 3, 4) has a high yield (73%), the purification method is simple, and the purity of the crude product (aspartic acid-methylimidazole) It can reach 95%, and the radioactivity after chelation of radionuclides is high (Fig. 5).
- the contrast agent is derived from an amino group (-NH 2 ) on the molecule of 1-(2-aminoethyl)-2-methyl-5-nitroimidazole and an alpha carboxylic acid (-COOH) on the L-aspartic acid molecule.
- amide an amide
- -COOH another carboxylic acid
- - ⁇ 2 another amino group on the L-aspartate molecule
- the 3 ⁇ 40 molecule was removed to form a second amide (-CONH-).
- the chemical reaction step (reaction formula 2), the final product yield (Fig. 6, 7, 8) yield (75%), the purification method is simple, the purity of the crude product (aspartic acid-aspartic acid-methylimidazole) Can reach >90%.
- the contrast agent is obtained by removing an amino group (-NH 2 ) from the molecule of 1-(2-aminoethyl)-2-methyl-5-nitroimidazole and an alpha carboxylic acid (-COOH) on the L-glutamic acid molecule. after ⁇ 2 0 molecules to form an amide (-CONH-), the other carboxylic acid (-COOH) in the molecule and then L- glutamic acid and aspartic acid L- amino group on another molecule (- ⁇ 2) removed ⁇ 20 molecules form a second amide (-CONH -).
- the contrast agent molecule has two L-glutamic acid and L-aspartic acid (Formula 14) linked in series.
- the chemical reaction step (reaction formula 3), the final product yield (Fig. 9, 10, 11) yield (62%), the purification method is simple, the purity of the crude product (aspartic acid-glutamic acid-methylimidazole) can be Reached >90%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020117011966A KR101389179B1 (ko) | 2008-10-29 | 2009-03-09 | 니트로이미다졸-아미노산 핵 저산소증 조영제 및 그 전구체 |
EP09822961A EP2366693A4 (en) | 2008-10-29 | 2009-03-09 | NITROIMIDAZOLAMINO-ACID COMPOUNDS FOR THE MICROSIZATION OF HYPOXIA AND INTERMEDIATE PRODUCTS FOR THE PREPARATION THEREOF |
KR1020137016069A KR101389258B1 (ko) | 2008-10-29 | 2009-03-09 | 니트로이미다졸-아미노산 핵 저산소증 조영제 및 그 전구체 |
US13/097,109 US9028799B2 (en) | 2008-10-29 | 2011-04-29 | Nitroimidazole-amino acid hypoxia contrast medium, preparation method and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102018979A CN101721720B (zh) | 2008-10-29 | 2008-10-29 | 硝咪唑-氨基酸化合型核素乏氧造影剂及其前体 |
CN200810201897.9 | 2008-10-29 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/097,109 Continuation US9028799B2 (en) | 2008-10-29 | 2011-04-29 | Nitroimidazole-amino acid hypoxia contrast medium, preparation method and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010048768A1 true WO2010048768A1 (zh) | 2010-05-06 |
Family
ID=42128193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/000246 WO2010048768A1 (zh) | 2008-10-29 | 2009-03-09 | 硝咪唑-氨基酸化合型核素乏氧造影剂及其前体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9028799B2 (zh) |
EP (1) | EP2366693A4 (zh) |
KR (2) | KR101389179B1 (zh) |
CN (1) | CN101721720B (zh) |
WO (1) | WO2010048768A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2593796A4 (en) * | 2010-07-16 | 2016-07-27 | Auckland Uniservices Ltd | BACTERIAL NITROREDUCTASE ENZYMES AND ASSOCIATED METHODS |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827208B (zh) * | 2012-09-25 | 2015-01-14 | 北京师范大学 | 99mTcO核标记蛋氨酸氨荒酸盐配合物的制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1438899A (zh) * | 2000-06-02 | 2003-08-27 | 德克萨斯州立大学董事会 | 乙二半胱氨酸(ec)-药物缀合物 |
EP1698351A2 (en) * | 2005-03-04 | 2006-09-06 | Taiwan Hopax Chems. Mfg. Co., Ltd | Glycopeptide compositions |
CN101203249A (zh) * | 2005-04-01 | 2008-06-18 | 德克萨斯大学体系董事会 | 多(肽)作为螯合剂:制造方法和用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4193979A (en) * | 1978-05-22 | 1980-03-18 | G. D. Searle & Co. | Sodium 3-[[[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]-amino]carbonyl]-2-pyridinecarboxylic acid and related compounds labeled with technetium-99m |
US5504055A (en) * | 1994-03-15 | 1996-04-02 | J.H. Biotech, Inc. | Metal amino acid chelate |
CA2266298A1 (en) * | 1999-03-19 | 2000-09-19 | Alfred Pollak | Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia |
US6692724B1 (en) * | 1999-10-25 | 2004-02-17 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US7067111B1 (en) * | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US20020094316A1 (en) * | 2001-01-09 | 2002-07-18 | Shuang Liu | Polypodal chelants for metallopharmaceuticals |
CN1131071C (zh) * | 2001-03-27 | 2003-12-17 | 北京大学 | 一种组织乏氧显像剂及其前体 |
US7261875B2 (en) * | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
WO2005087275A2 (en) * | 2004-03-11 | 2005-09-22 | Board Of Regents, The University Of Texas System | Metal radiolabeled pet imaging agents |
DE102005063244A1 (de) * | 2005-12-21 | 2007-06-28 | Eberhard-Karls-Universität Tübingen | Modifiziertes 2-Nitroimidazol-Derivat |
WO2008054824A2 (en) * | 2006-11-02 | 2008-05-08 | The Trustess Of The University Of Pennsylvania | Methods for differential detection of hypoxic tissue in a mammalian subject |
CN101024657B (zh) * | 2007-04-02 | 2012-07-18 | 北京师范大学 | 一种99mTc标记的甲硝唑磷酸酯配合物及其制备方法 |
-
2008
- 2008-10-29 CN CN2008102018979A patent/CN101721720B/zh active Active
-
2009
- 2009-03-09 KR KR1020117011966A patent/KR101389179B1/ko not_active IP Right Cessation
- 2009-03-09 KR KR1020137016069A patent/KR101389258B1/ko not_active IP Right Cessation
- 2009-03-09 WO PCT/CN2009/000246 patent/WO2010048768A1/zh active Application Filing
- 2009-03-09 EP EP09822961A patent/EP2366693A4/en not_active Withdrawn
-
2011
- 2011-04-29 US US13/097,109 patent/US9028799B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1438899A (zh) * | 2000-06-02 | 2003-08-27 | 德克萨斯州立大学董事会 | 乙二半胱氨酸(ec)-药物缀合物 |
EP1698351A2 (en) * | 2005-03-04 | 2006-09-06 | Taiwan Hopax Chems. Mfg. Co., Ltd | Glycopeptide compositions |
CN101203249A (zh) * | 2005-04-01 | 2008-06-18 | 德克萨斯大学体系董事会 | 多(肽)作为螯合剂:制造方法和用途 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2593796A4 (en) * | 2010-07-16 | 2016-07-27 | Auckland Uniservices Ltd | BACTERIAL NITROREDUCTASE ENZYMES AND ASSOCIATED METHODS |
US10357577B2 (en) | 2010-07-16 | 2019-07-23 | Auckland Uniservices Limited | Bacterial nitroreductase enzymes and methods relating thereto |
Also Published As
Publication number | Publication date |
---|---|
KR101389258B1 (ko) | 2014-04-24 |
KR20110077019A (ko) | 2011-07-06 |
US9028799B2 (en) | 2015-05-12 |
EP2366693A4 (en) | 2012-07-11 |
US20110206604A1 (en) | 2011-08-25 |
CN101721720B (zh) | 2011-08-24 |
KR20130089274A (ko) | 2013-08-09 |
KR101389179B1 (ko) | 2014-04-24 |
EP2366693A1 (en) | 2011-09-21 |
CN101721720A (zh) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7219497B2 (ja) | Psma結合剤及びその使用 | |
EP2086924B1 (de) | [f-18]markierte l-glutaminsäure, [f-18]markiertes l-glutamin, ihre derivate und ihre verwendung sowie verfahren zu ihrer herstellung | |
CA2723596C (en) | [f-18]-labelled l-glutamic acid and l-glutamine derivatives (i), their use and processes for their preparation | |
WO2009002529A2 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents | |
Mallia et al. | On the structural modification of 2-nitroimidazole-99mTc (CO) 3 complex, a hypoxia marker, for improving in vivo pharmacokinetics | |
Mukai et al. | Design of Ga–DOTA-based bifunctional radiopharmaceuticals: Two functional moieties can be conjugated to radiogallium–DOTA without reducing the complex stability | |
JP5085824B2 (ja) | 低酸素の検出のために有用な化合物の製造 | |
AU2015203742A1 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents | |
WO2010048768A1 (zh) | 硝咪唑-氨基酸化合型核素乏氧造影剂及其前体 | |
AU2013324636B2 (en) | Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma | |
US20180369428A1 (en) | Radioactive probe for detecting hydrogen sulfide | |
RU2730507C1 (ru) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе | |
EP3908331A1 (en) | Radiodrug for diagnostic/therapeutic use in nuclear medicine and radio-guided medicine | |
CN115772183A (zh) | 一类吲哚乙基氟硼酸衍生物及其制备方法和用途 | |
EP2644601A1 (en) | Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09822961 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20117011966 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2009822961 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3686/CHENP/2011 Country of ref document: IN Ref document number: 2009822961 Country of ref document: EP |